EU Medical Device Regulation (MDR)

The European Union's medical-device regulatory framework — Regulation (EU) 2017/745, replacing the prior Medical Device Directive (MDD, 93/42/EEC) that governed medical devices in the EU since 1993. MDR became fully applicable in May 2021 (after multiple deadline extensions), and applies to all medical devices marketed in the EU and EEA. Imaging-equipment OEMs operate under both FDA (US market) and MDR (EU market) frameworks simultaneously; the requirements differ enough that compliance documentation and post-market surveillance commitments are not directly transferable.

For imaging equipment specifically, MDR raised the bar materially over MDD on three axes: clinical evidence requirements (more demanding clinical-evaluation standards, particularly for higher-risk devices), post-market surveillance (formalized PMS plans, periodic safety update reports, vigilance reporting), and technical documentation (structured technical files reviewed by Notified Bodies). The transition cost has been substantial across the industry, with multiple OEMs withdrawing legacy products from the EU market rather than re-certifying under MDR.

Risk classification

MDR uses a four-tier risk classification analogous to (but not identical with) FDA:

Class I — low-risk (most ultrasound transducers as accessories, some non-active devices).
Class IIa — medium-low risk (most ultrasound systems, fluoroscopy / DR systems).
Class IIb — medium-high risk (CT, MRI, mammography, most interventional X-ray, PET, nuclear medicine, linacs at the higher tier).
Class III — high-risk (implantables, most life-support, some specialized therapeutic devices). Most diagnostic imaging is below this tier; therapeutic radiation devices may sit at the Class III boundary depending on classification rules.

Notified Body certification

Class IIa, IIb, III devices require certification by a designated Notified Body (NB) — independent third-party conformity-assessment organizations.
Notified Body audit + technical-file review is the principal path to CE marking under MDR.
Notified Body capacity has been a transition-era bottleneck — limited NB designation under MDR slowed certification throughput across the industry.
Class I (non-sterile, non-measuring) devices can self-declare conformity; no NB involvement.

Key MDR requirements specific to imaging equipment

Clinical evaluation — substantially more demanding than under MDD. Equivalence-based pathways (where a new device claims equivalence to a predicate) are tightened; clinical-data requirements increased.
Post-Market Clinical Follow-up (PMCF) — ongoing collection of clinical outcomes data is required for higher-risk devices. PMCF plans are part of the technical file and Notified Body audit.
Unique Device Identification (UDI) — MDR requires UDI assignment for all medical devices, supporting traceability across the supply chain. UDI is registered in the EUDAMED European database.
EUDAMED database — central EU database for device registration, vigilance reporting, and clinical-investigation tracking. Implementation has been phased; not all modules are fully operational.
Person Responsible for Regulatory Compliance (PRRC) — every MDR-regulated manufacturer must designate a qualified PRRC.
Importer / distributor obligations — MDR places more responsibility on importers and distributors than MDD did. Refurbishers / used-equipment distributors operating in the EU face additional documentation requirements.

Refurbishment / used-device implications

MDR's treatment of refurbished and used medical devices is more demanding than the prior MDD framework:

"Fully refurbished" devices placed on the EU market may be considered new devices for MDR purposes, triggering full re-certification requirements.
Used-device sales to EU end users have specific obligations on the seller (importer / distributor) for technical-file maintenance, traceability, and post-market surveillance participation.
Cross-border refurb between non-EU and EU markets is a more complex regulatory transaction under MDR than under MDD.
The exact line between "refurbished" (subject to lighter-touch requirements) and "fully refurbished" (subject to full new-device requirements) is interpretation-sensitive and OEM / Notified Body specific.

Vigilance and incident reporting

Serious incidents must be reported to the relevant National Competent Authority within tight timelines (15 days, or 2 days for serious public-health threats).
Field safety corrective actions (device recalls, design fixes propagated to the field) require Field Safety Notices to all affected users and reporting to Competent Authorities.
Periodic Safety Update Reports (PSUR) — for higher-risk devices, periodic aggregate safety reporting to authorities and Notified Body.

Comparison with FDA framework

MDR is more clinical-evidence-heavy than FDA 510(k) for equivalent device classes — 510(k) substantial-equivalence pathway has no direct MDR analog.
MDR PMS requirements are formalized in a way that exceeds FDA MDR (Medical Device Reporting) post-market obligations.
Notified Body involvement in MDR replaces the FDA-internal review for higher-risk devices in the US.
Both frameworks require quality-management system compliance — ISO 13485 in EU, FDA Quality System Regulation (21 CFR 820) in the US.

In Vitro Diagnostic Regulation (IVDR)

The EU's parallel framework for in-vitro diagnostics — Regulation (EU) 2017/746 — became applicable May 2022. Software-only products that perform diagnostic functions (e.g., AI-based image-analysis tools) may fall under IVDR rather than MDR depending on classification rules. Dual MDR / IVDR navigation is increasingly common for imaging-AI products.